Evidence map›Paper›PMID 37548777›Full record

ArticleMedical oncology (Northwood, London, England)2023

Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells.

Mohaddeseh Hedayat, Mohammad Rafi Khezri, Reza Jafari, Hassan Malekinejad, Naime Majidi Zolbanin

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Celecoxib in oncology: targeting the COX-2/PGEFrontiers in pharmacology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mohaddeseh HedayatStudent Research Committee, Urmia University of Medical Sciences, Urmia, Iran.ORCID http://orcid.org/0000-0002-7709-8670
Mohammad Rafi KhezriStudent Research Committee, Urmia University of Medical Sciences, Urmia, Iran.ORCID http://orcid.org/0000-0002-4280-0378
Reza JafariCellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran.ORCID http://orcid.org/0000-0003-2036-9043
Hassan MalekinejadExperimental and Applied Pharmaceutical Sciences Research Center, Urmia University of Medical Sciences, Urmia, Iran.ORCID http://orcid.org/0000-0001-9941-6847
Naime Majidi ZolbaninExperimental and Applied Pharmaceutical Sciences Research Center, Urmia University of Medical Sciences, Urmia, Iran. majidiz.n@umsu.ac.ir.ORCID http://orcid.org/0000-0001-7286-5319
Urmia University · IR

Funding

Urmia University of Medical Sciences 10243
6 · The paper itself

Abstract

Although triple-negative breast cancer accounts for less than one-fifth of breast cancers, it has a higher rate of metastasis and mortality. This study investigated the effects of combination treatment with paclitaxel and celecoxib on the expression of genes involved in the apoptosis of triple-negative metastatic breast cancer cells. MDA-MB-231 cells were cultured and then treated with certain concentrations of celecoxib (CLX), paclitaxel (PTX), and combination of them for 24 and 48 h. Cell viability was assessed by the MTT method. The real-time PCR method was utilized to assess the expression level of the genes involved in apoptosis. Western blotting was used for evaluating protein expression. IC

Indexed as

Breast NeoplasmsTriple Negative Breast NeoplasmsApoptosisbcl-2-Associated X ProteinCaspase 3CelecoxibCell Line, TumorFemaleHumansPaclitaxelProto-Oncogene Proteins c-bcl-2bcl-2-Associated X ProteinCaspase 3CelecoxibPaclitaxelProto-Oncogene Proteins c-bcl-2ApoptosisCelecoxibCox-2MDA-MB-231PaclitaxelTriple-negative breast cancer

Identifiers

PMID37548777
OpenAlexW4385620002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.